Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205280 | 0.89 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL28594745 | 0.82 | GSK3B (0.70) | GSK3BPTPN1SRD5A2ALDH1A1 | |
| SCHEMBL18849535 | 0.82 | GSK3B (1.00) | GSK3BPTPN1TSHRALDH1A1ALOX15 | |
| SCHEMBL7621 | 0.82 | GSK3B (1.00) | GSK3BPTPN1TSHRALDH1A1ALOX15 | |
| SCHEMBL689331 | 0.82 | GSK3B (0.83) | GSK3BPTPN1ALDH1A1 | |
| SCHEMBL19331717 | 0.82 | GSK3B (1.00) | GSK3BPTPN1TSHRALDH1A1ALOX15 | |
| SCHEMBL5549541 | 0.81 | TP53 (0.55) | GSK3BPTPN1TSHRTP53SRD5A2 | |
| Terephthalic Acid SCHEMBL1006723 | 0.81 | TSHR (0.92) | TSHRTP53SRD5A2CA12CA1 | |
| Methane SCHEMBL7161301 | 0.80 | GSK3B (0.95) | GSK3BPTPN1ALDH1A1ALOX15 | |
| Hydrogen Sulfide SCHEMBL7496567 | 0.80 | GSK3B (0.95) | GSK3BPTPN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114075187-B | Carbonyl pyrazole antitumor compound as well as preparation method and application thereof | 山东大学 | 2023-05-12 | — | — | CN | claimed |
| CN-114075187-A | Carbonyl pyrazole anti-tumor compound and preparation method and application thereof | 山东大学 | 2022-02-22 | — | — | CN | claimed |
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | claimed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | claimed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | claimed |
| US-20250290137-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12378209-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-4069697-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12351871-B2 | Substituted coumarin dyes and uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-07-08 | — | — | US | disclosed |
| CN-120058701-A | Thioether structure-containing targeted PHGDH active molecular probe, preparation method and application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-120040373-A | Thiazole GPR52 modulator compound | 江苏海洋大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20250032462-A1 | BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-01-30 | — | — | US | disclosed |
| EP-0585155-A1 | Trifluoromethylketone derivatives of peptides having HLE inhibiting activity, their preparation and pharmaceutical composition | ADIR ET COMPAGNIE (FR) | 1994-03-02 | — | — | EP | disclosed |
| US-5256543-A | Human leukocyte antigens | SANGSTAT MEDICAL CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1993004372-A1 | HLA TYPING | SANGSTAT MEDICAL CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1992021030-A1 | HLA TYPING | SANGSTAT MEDICAL CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4636509-A | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, pharmaceutical compositions containing them and a method therefor | GLAXO GROUP LIMITED (GB) | 1987-01-13 | — | — | US | disclosed |
| EP-0044704-B1 | SUBSTITUTED PYRIMIDIN-2-ONES, THE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1986-05-07 | — | — | EP | disclosed |
| EP-0044704-A1 | Substituted pyrimidin-2-ones, the salts thereof, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-01-27 | — | — | EP | disclosed |
| US-4263393-A | Novel electron donor precursors and photographic element containing them | EASTMAN KODAK COMPANY (US) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032462-A1 | BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY | BAX, BAD, BID | GSK3B 2832/4885PTPN1 4488/4885TSHR 4621/4885 |
| US-20250290137-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | FBL, DUT, PHAX | GSK3B 4086/4885PTPN1 4723/4885TSHR 4811/4885 |
| US-12378209-B2 | Protease inhibitors | MMP26, CTSK, TMPRSS6 | GSK3B 2927/4885PTPN1 3817/4885TSHR 891/4885 |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | GSK3B 2307/4885PTPN1 2513/4885TSHR 4206/4885 |
| US-12351871-B2 | Substituted coumarin dyes and uses as fluorescent labels | FBL, DUT, PHAX | GSK3B 4086/4885PTPN1 4723/4885TSHR 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.